Top-of-the-art cytometry as a novel tool to aid in lung cancer immunotherapy

Transl Lung Cancer Res. 2023 May 31;12(5):957-961. doi: 10.21037/tlcr-23-80. Epub 2023 Apr 6.

Patricia Mondelo-Macía^{1

2}, Luis León-Mateos^{3

4

5}, David Bernardo^{6

7}, Roberto Díaz-Peña⁸

¹ Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain.
² Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain.
³ Department of Medical Oncology, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain.
⁴ Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain.
⁵ Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Santiago de Compostela, Spain.
⁶ Mucosal Immunology Lab, Unidad de Excelencia del Instituto de Biomedicina y Genética Molecular (IBGM, Universidad de Valladolid-CSIC), Valladolid, Spain.
⁷ Centro de Investigación Biomédicas en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
⁸ Fundación Pública Galega de Medicina Xenómica, Servicio Galego de Saúde (SERGAS), Grupo de Medicina Xenomica-USC, Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain.

No abstract available

Keywords: Non-small cell lung cancer (NSCLC); immune-related adverse events (irAEs); immunotherapy; mass cytometry; toxicity.

Publication types